Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SHERLOC: A Phase 2 Study of MM-121 in Combination With Docetaxel Versus Docetaxel Alone in Patients With Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Merrimack Pharmaceuticals Inc.)

NCT02387216 is registered in ClinicalTrials.gov with Elevation Oncology as lead sponsor.

NCT NCT02387216
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02387216 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SHERLOC: A Phase 2 Study of MM-121 in Combination With Docetaxel Versus Docetaxel Alone in Patients With Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Merrimack Pharmaceuticals Inc.)
Lead sponsor
Elevation Oncology
Phase
Phase 2
Overall status
Terminated
Start date
February 1, 2015
Completion date
January 2, 2019
Enrollment
153 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma, heregulin, non-small cell lung cancer, nsclc